Assessment of serum laminin and hyaluronic acid as markers of hepatic fibrosis in patients with chronic Hepatitis B.
Main Article Content
Keywords
laminin, hyaluronic acid, hepatic fibrisis, chronic Hepatitis B, chronic liver disease
Abstract
Background: Hepatitis B virus (HBV) is a major cause of chronic liver disease worldwide. Fibrosis of hepatic parenchyma has been reported as a common pathway to complications of chronic liver disease. There is a need to monitor fibrosis in these patients to abort or delay disease progression following treatment. Liver biopsy is recognized as the gold standard for disease monitoring; however, the procedure is invasive and bedeviled with potential complications. For these reasons, non-invasive biomarkers of fibrosis are now being evaluated as alternatives to liver biopsy. The study aimed to assess the characteristics of laminin, and hyaluronic acid as markers of hepatic fibrosis in patients with chronic hepatitis B.
Methodology: One hundred participants with HBV-induced chronic liver disease (CLD) were recruited for the study. A liver biopsy was conducted, and the degree of hepatic fibrosis was scored using the Metavir scoring system. Serum levels of the biomarkers were determined using enzyme-linked immunosorbent assay (ELISA) technique. Medians and interquartile ranges were compared using the Mann-Whitney U test. The degree of correlation between continuous variables was determined using Spearman’s correlation analysis. Statistical significance was set at p ≤ 0.05.
Results: Serum laminin was significantly higher in participants with hepatic fibrosis: 39.09 (27.6-89.4) ng/ml [median (interquartile range)], vs 24.3 (21.5-31.9) ng/ml, p = 0.001, Hyaluronic acid was significantly higher in participants with hepatic fibrosis: 45.1 (26.9-94.4) ng/ml vs 23.1 (12.7-35.7) ng/ml, p < 0.001. There was a strong significant positive correlation of both serum laminin and hyaluronic acid with Metavir score in the study participants (r=0.766, p<0.001; r=0.708, p<0.001 respectively). At a serum laminin concentration of 44.6 ng/ml, sensitivity and specificity for detecting moderate to severe hepatic fibrosis were 86.8% and 88.7% respectively, with an area under the curve (AUC) of 0.943 on the Receiver Operator Characteristic (ROC) curve. The sensitivity and specificity of hyaluronic acid for detecting moderate to severe hepatic fibrosis were 81.6% and 85.5% at a serum concentration of 53.5 ng/ml. AUC was 0.930 on the ROC curve.
Conclusion: This study underscores the evidence that laminin and hyaluronic acid may be helpful clinically in identifying patients with moderate to severe hepatic fibrosis. Serum laminin had a slightly better diagnostic ability than hyaluronic acid in the study participants. Further studies are needed to elucidate our findings.
References
2. Younossi ZM, Wong G, Anstee QM, Henry L. The Global Burden of Liver Disease. Clin Gastroenterol Hepatol. 2023 Jul;21(8):1978-91. doi: 10.1016/j.cgh.2023.04.015.
3. GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol 2022;7:796–829.
4. Lesi OA, Kehinde MO, Omilabu SA. Prevalence of the Hepatitis B “e” Antigen in Nigerian Patients with Chronic Liver Disease. Nigerian Quarterly Journal of Hospital Medicine. 2008;14(1):1–4.
5. K. Böttcher, M. Pinzani, Pathophysiology of liver fibrosis and the methodological barriers to the development of anti- fibrogenic agents, Adv. Drug Deliv. Rev. (2017), http://dx.doi.org/10.1016/j.addr.2017.05.016.
6. Randazzo C, Licata A, Luigi P. Liver Biopsy - Indications, Procedures, Results [Internet]. Liver Biopsy - Indications, Procedures, Results. InTech; 2012. Available from: http://dx.doi.org/10.5772/52616.
7. Bason BR. Cirrhosis and its complications. In: Dan L. Lungo, Dennis L. Kasper, Larry J. Jameson, Anthony S Fauci, Stephen L. Hauser JL, editors. Harrison’s Principles of Internal Medicine. 18th ed. New York; 2012. p. 2592.
8. Baranova A, Lal P, Birerdinc A, Younossi ZM, Schiff E, Lee S, et al. Non-Invasive markers for hepatic fibrosis. BMC Gastroenterology. 2011 Dec 17;11(1):91.
9. Mutchnick MG, Lederman HM, Missirian A, Johnson AG. In vitro synthesis of IgG by peripheral blood lymphocytes in chronic liver disease. Clinical and experimental immunology. 1981;43(2):370–5.
10. Poole AR. Proteoglycans in health and disease: structures and functions. The Biochemical journal. 1986;236(1):1–14.
11. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. Journal of internal medicine. 1997;242(1):27–33.
12. Rostami S, Parsian H. Hyaluronic Acid: From Biochemical Characteristics to its Clinical Translation in Assessment of Liver Fibrosis. Hepat Mon. 2013;13(12):e13787. https://doi.org/10.5812/hepatmon.13787.
13. Leroy V. Other non-invasive markers of liver fibrosis. Gastroentérologie Clinique et Biologique. 2008;32(6):52–7.
14. McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. Journal of gastroenterology and hepatology. 2000;15(8):945–51.
15. FB Shamkhi, MI Hamzah, FA AL Abbudi, MH Alrekabi.The Role of Serum Laminin and Serum Hyaluronic Acid as Biomarkers for the Detection and Staging of Liver Fibrosis in a Sample of Iraqi Patients with Chronic Liver Disease. HIV Nursing. 22 (2), 1956–60.
16. Younesi S, Parsian H. Diagnostic accuracy of glycoproteins in the assessment of liver fibrosis: A comparison between laminin, fibronectin, and hyaluronic acid. Turk J Gastroenterol 2019; 30(6): 524-31.
17. Li F, Zhu C-L, Zhang H, Huang H, Wei Q, Zhu X, et al. Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B. The Brazilian Journal of Infectious Diseases. 2012;16(1):9–14.
18. Abdel-Ghaffar TY, Behairy BE, El-Shaheed AA, Mahdy K, El-Batanony M, Hussein MH et al. Clinical Benefits of Biochemical Markers of Fibrosis in Egyptian Children With Chronic Liver Diseases. Gastroenterology Res. 2010;3(6):262-271. doi: 10.4021/gr246w.
19. Santos VN dos, Leite-Mór MMB, Kondo M, Martins JR, Nader H, Lanzoni VP, et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Brazilian Journal of Medical and Biological Research. 2005;38(5):747–53.
20. Hafez AM, Sheta YS, Ibrahim MH, Elshazly SA. Could serum laminin replace liver biopsy as gold standard for predicting significant fibrosis in patients with chronic hepatitis B? Clinical and histological study. Journal of Asian Scientific Research. 2013;3(2):128–39.
21. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World Journal of Gastroenterology 2006 p. 3682–94.
22. Menghini G. One-second needle biopsy of the liver. Gastroenterology. 1958;35(2):190–9.
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996 Aug;24(2):289-93. doi: 10.1002/hep.510240201.